Pharvaris N.V.

PHVS

Cena:

$ 29.68

-0.86 (-2.82%)

Valuace

Růst

Zdraví

Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři

Souhrn

Finanční data

Pro investory

Předpovědi

Zprávy

Dividendy

Zisky

Návštěvnost webu

Akcionáři

Zprávy

Zahraniční články

Tiskové zprávy

Dokumenty ke stáhnutí

Pharvaris N.V. (PHVS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

15:10 13-05-2026

Pharvaris N.V. (PHVS) Presents at Bank of America Global Healthcare Conference 2026 Transcript...

Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update

16:05 12-05-2026

Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE ...

Pharvaris Chief Medical Officer Sells 14,000 Shares for $427,000

16:29 11-05-2026

This clinical-stage biotech, focused on rare disease therapies, reported a notable insider sale amid...

Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares

16:15 11-05-2026

ZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a...

Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares

6:00 08-05-2026

ZUG, Switzerland, May 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a...

For Pharvaris Investors, the Director's Sale Matters Less Than What's Coming Next

20:22 29-04-2026

This biopharma innovator in rare disease therapies reported a notable insider sale amid a year of st...

Pharvaris (NASDAQ:PHVS) CEO Berndt Modig Sells 2,292 Shares of Stock

4:56 21-04-2026

Pharvaris N.V. (NASDAQ: PHVS - Get Free Report) CEO Berndt Modig sold 2,292 shares of the business's...

Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference

6:50 20-04-2026

ZUG, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharm...

Pharvaris' CEO Dumped Over 23,000 Company Shares. Here's What That Means for Investors.

10:24 13-04-2026

This clinical-stage biotech focused on rare disease therapies reported a notable insider sale amid a...

Tudor Investment Corp ET AL Takes Position in Pharvaris N.V. $PHVS

5:52 13-04-2026

Tudor Investment Corp ET AL purchased a new stake in Pharvaris N.V. (NASDAQ: PHVS) during the third ...

Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

6:50 02-04-2026

ZUG, Switzerland, April 02, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharm...

Does Pharvaris (PHVS) Have the Potential to Rally 59.93% as Wall Street Analysts Expect?

10:55 01-04-2026

The mean of analysts' price targets for Pharvaris (PHVS) points to a 59.9% upside in the stock. Whil...

Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology

6:50 20-03-2026

ZUG, Switzerland, March 20, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharm...

Pharvaris N.V. (NASDAQ:PHVS) Receives $41.70 Consensus Target Price from Brokerages

1:28 16-03-2026

Shares of Pharvaris N.V. (NASDAQ: PHVS - Get Free Report) have earned an average recommendation of "...

Pharvaris N.V. $PHVS Shares Purchased by General Atlantic L.P.

3:50 14-03-2026

General Atlantic L.P. raised its stake in Pharvaris N.V. (NASDAQ: PHVS) by 6.6% during the third qua...

Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology

6:50 11-03-2026

ZUG, Switzerland, March 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharm...

Pharvaris N.V. (NASDAQ:PHVS) Receives Average Recommendation of “Moderate Buy” from Brokerages

3:32 16-02-2026

Shares of Pharvaris N.V. (NASDAQ: PHVS - Get Free Report) have earned a consensus rating of "Moderat...

Pharvaris N.V. (NASDAQ:PHVS) Sees Large Increase in Short Interest

4:34 05-02-2026

Pharvaris N.V. (NASDAQ: PHVS - Get Free Report) was the recipient of a significant increase in short...

Pharvaris Outlines 2026 Strategic Priorities

6:50 12-01-2026

Topline data from CHAPTER-3, a pivotal study of deucrictibant for prophylactic treatment of HAE atta...

This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy?

7:00 09-12-2025

Austin-based Saturn V Capital Management acquired 886,332 shares of Pharvaris in the third quarter. ...

PHARVARIS TO PRESENT CLINICAL DATA AT THE AAAAI 2026 ANNUAL MEETING

10-02-2026

PIVOTAL PHASE 3 DATA FROM RAPIDE-3 OF DEUCRICTIBANT FOR THE ON-DEMAND TREATMENT OF HAE ATTACKS TO BE...

Více zde

PHARVARIS OUTLINES 2026 STRATEGIC PRIORITIES

12-01-2026

TOPLINE DATA FROM CHAPTER-3, A PIVOTAL STUDY OF DEUCRICTIBANT FOR PROPHYLACTIC TREATMENT OF HAE ATTA...

Více zde

PHARVARIS ANNOUNCES POSITIVE TOPLINE DATA FROM RAPIDE-3 PIVOTAL STUDY CONFIRMING POTENTIAL OF DEUCRICTIBANT FOR ON-DEMAND TREATMENT OF HAE ATTACKS

03-12-2025

PRIMARY ENDPOINT MET; MEDIAN TIME TO ONSET OF SYMPTOM RELIEF ACHIEVED IN 1.28 HOURS, SIGNIFICANTLY ...

Více zde

PHARVARIS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

12-11-2025

TOPLINE DATA FOR RAPIDE-3, A PIVOTAL PHASE 3 STUDY OF DEUCRICTIBANT IMMEDIATE-RELEASE CAPSULE FOR TH...

Více zde

DATA SUPPORTING THE POTENTIALLY DIFFERENTIATED PHARVARIS PORTFOLIO PRESENTED AT ACAAI 2025 ANNUAL SCIENTIFIC MEETING

10-11-2025

ZUG, SWITZERLAND, NOV. 10, 2025 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMA...

Více zde

PHARVARIS TO PRESENT CLINICAL DATA AT THE ACAAI 2025 ANNUAL SCIENTIFIC MEETING

23-10-2025

ZUG, SWITZERLAND, OCT. 23, 2025 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMA...

Více zde

PHARVARIS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

12-08-2025

TOPLINE RESULTS FOR RAPIDE-3, A PIVOTAL PHASE 3 STUDY OF DEUCRICTIBANT FOR THE ON-DEMAND TREATMENT O...

Více zde

PHARVARIS ANNOUNCES PRICING OF UPSIZED $175 MILLION PUBLIC OFFERING OF ORDINARY SHARES AND PRE-FUNDED WARRANTS

22-07-2025

ZUG, SWITZERLAND, JULY 22, 2025 (GLOBE NEWSWIRE) -- PHARVARIS N.V. (“PHARVARIS,” NASDAQ: PHVS), ...

Více zde

PHARVARIS ANNOUNCES PROPOSED PUBLIC OFFERING OF ORDINARY SHARES

22-07-2025

ZUG, SWITZERLAND, JULY 22, 2025 (GLOBE NEWSWIRE) -- PHARVARIS N.V. (“PHARVARIS,” NASDAQ: PHVS), ...

Více zde

PHARVARIS UPDATES TIMING OF TOPLINE DATA ANNOUNCEMENT FOR RAPIDE-3 PIVOTAL PHASE 3 STUDY TO THE FOURTH QUARTER OF 2025

10-07-2025

ZUG, SWITZERLAND, JULY 10, 2025 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMA...

Více zde

PHARVARIS ANNOUNCES CLINICAL TRIAL DATA HIGHLIGHTING DEUCRICTIBANT FOR THE TREATMENT OF HAE TO BE PRESENTED AT THE 2025 US HAEA NATIONAL SUMMIT

27-06-2025

ZUG, SWITZERLAND, JUNE 27, 2025 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMA...

Více zde

PHARVARIS PRESENTS DATA HIGHLIGHTING THE POTENTIAL FOR DEUCRICTIBANT TO PREVENT AND TREAT BRADYKININ-MEDIATED ANGIOEDEMA ATTACKS AT THE EAACI CONGRESS

16-06-2025

ZUG, SWITZERLAND, JUNE 16, 2025 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMA...

Více zde

PHARVARIS ANNOUNCES ANNUAL MEETING OF SHAREHOLDERS

10-06-2025

ZUG, SWITZERLAND, JUNE 10, 2025 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMA...

Více zde

PHARVARIS PRESENTS DATA SUPPORTING ONGOING CLINICAL DEVELOPMENT OF DEUCRICTIBANT IN BRADYKININ-MEDIATED ANGIOEDEMA

02-06-2025

ZUG, SWITZERLAND, JUNE 02, 2025 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMA...

Více zde

PHARVARIS TO PRESENT DEUCRICTIBANT CLINICAL DATA AND EXPLORATORY BIOMARKER DATA AT UPCOMING CONGRESSES

19-05-2025

ZUG, SWITZERLAND, MAY 19, 2025 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMAC...

Více zde

PHARVARIS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

13-05-2025

ZUG, SWITZERLAND, MAY 13, 2025 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMAC...

Více zde

PHARVARIS TO HOST A VIRTUAL R&D CALL “DEUCRICTIBANT: BEYOND HAE TYPE 1/2” ON JUNE 4

12-05-2025

EXPANSION OF POTENTIAL TREATMENT APPLICATIONS OF DEUCRICTIBANT IN PEOPLE LIVING WITH BRADYKININ-MEDI...

Více zde

PHARVARIS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

07-04-2025

ZUG, SWITZERLAND, APRIL 07, 2025 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARM...

Více zde

PHARVARIS ANNOUNCES ORPHAN DESIGNATION GRANTED TO DEUCRICTIBANT BY THE EUROPEAN COMMISSION

01-04-2025

ZUG, SWITZERLAND, APRIL 01, 2025 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARM...

Více zde

PHARVARIS PRESENTS LONG-TERM CLINICAL DATA OF DEUCRICTIBANT FOR THE PREVENTION AND TREATMENT OF HAE ATTACKS AT THE 2025 AAAAI/WAO JOINT CONGRESS

03-03-2025

ZUG, SWITZERLAND, MARCH 03, 2025 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARM...

Více zde

PHARVARIS TO PARTICIPATE IN THE LEERINK PARTNERS GLOBAL HEALTHCARE CONFERENCE 2025

03-03-2025

ZUG, SWITZERLAND, MARCH 03, 2025 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHAR...

Více zde

PHARVARIS OUTLINES 2025 STRATEGIC PRIORITIES

13-01-2025

ZUG, SWITZERLAND, JAN. 13, 2025 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMA...

Více zde

PHARVARIS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS RECENT BUSINESS UPDATES

13-11-2024

ZUG, SWITZERLAND, NOV. 13, 2024 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMA...

Více zde

PHARVARIS TO PARTICIPATE IN THE GUGGENHEIM HEALTHCARE INNOVATION CONFERENCE

12-11-2024

ZUG, SWITZERLAND, NOV. 12, 2024 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMA...

Více zde

PHARVARIS ANNOUNCES DATA HIGHLIGHTING DEUCRICTIBANT FOR THE TREATMENT OF HAE TO BE PRESENTED AT UPCOMING SCIENTIFIC MEETINGS

16-10-2024

ZUG, SWITZERLAND, OCT. 16, 2024 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMA...

Více zde

PHARVARIS TO HOST VIRTUAL INVESTOR EVENT ON OCTOBER 23, 2024

15-10-2024

ZUG, SWITZERLAND, OCT. 15, 2024 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMA...

Více zde

PHARVARIS ANNOUNCES DATA HIGHLIGHTING DEUCRICTIBANT FOR THE TREATMENT OF HAE TO BE PRESENTED AT THE 2024 HAEI GLOBAL LEADERSHIP WORKSHOP

03-10-2024

ZUG, SWITZERLAND, OCT. 03, 2024 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARMA...

Více zde

PHARVARIS PROVIDES BUSINESS UPDATE AND EXPANDS DEVELOPMENT PROGRAM FOR DEUCRICTIBANT

05-09-2024

ZUG, SWITZERLAND, SEPT. 05, 2024 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARM...

Více zde

PHARVARIS PRESENTS DEUCRICTIBANT LONG-TERM EXTENSION DATA FOR BOTH THE PROPHYLACTIC AND ON-DEMAND TREATMENT OF HAE AT THE BRADYKININ SYMPOSIUM 2024

05-09-2024

ZUG, SWITZERLAND, SEPT. 05, 2024 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARM...

Více zde

PHARVARIS PRESENTS DATA AT THE BRADYKININ SYMPOSIUM 2024

05-09-2024

ZUG, SWITZERLAND, SEPT. 05, 2024 (GLOBE NEWSWIRE) -- PHARVARIS (NASDAQ: PHVS), A LATE-STAGE BIOPHARM...

Více zde

Dokumenty nejsou k dispozici